Patient and disease characteristics
| Characteristic . | Number (%) . |
|---|---|
| Total no. of patients, N | 98 |
| Median age at diagnosis (range), y | 4.6 (0.2-15.6) |
| Age (in years) at start of chemotherapy, n (%) | |
| <1 | 4 (4) |
| 1-2 | 17 (17) |
| 3-5 | 40 (41) |
| 6-10 | 20 (20) |
| 11-15 | 17 (17) |
| Sex, male, n (%) | 52 (53) |
| Type of ALL, n (%) | |
| B cell | 88 (90) |
| T cell | 10 (10) |
| EOI outcome, n (%) | |
| MRD negative | 66 (67) |
| MRD positive | 22 (22) |
| Died | 7 (7) |
| Unknown | 3 (3) |
| CNS status, n (%) | |
| CNS 1 | 80 (82) |
| CNS 2 | 3 (3) |
| CNS 3 | 9 (9) |
| Unknown | 6 (6) |
| Median follow-up of survivors (range), mo | 19 (0.5-66) |
| Characteristic . | Number (%) . |
|---|---|
| Total no. of patients, N | 98 |
| Median age at diagnosis (range), y | 4.6 (0.2-15.6) |
| Age (in years) at start of chemotherapy, n (%) | |
| <1 | 4 (4) |
| 1-2 | 17 (17) |
| 3-5 | 40 (41) |
| 6-10 | 20 (20) |
| 11-15 | 17 (17) |
| Sex, male, n (%) | 52 (53) |
| Type of ALL, n (%) | |
| B cell | 88 (90) |
| T cell | 10 (10) |
| EOI outcome, n (%) | |
| MRD negative | 66 (67) |
| MRD positive | 22 (22) |
| Died | 7 (7) |
| Unknown | 3 (3) |
| CNS status, n (%) | |
| CNS 1 | 80 (82) |
| CNS 2 | 3 (3) |
| CNS 3 | 9 (9) |
| Unknown | 6 (6) |
| Median follow-up of survivors (range), mo | 19 (0.5-66) |